Literature DB >> 7737577

An alternative view of 5-ASA formulations.

J Rhodes, G A Coles.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1995        PMID： 7737577      PMCID： PMC1382512          DOI： 10.1136/gut.36.4.639

Source DB:  PubMed          Journal:  Gut        ISSN： 0017-5749            Impact factor:   23.059


× No keyword cloud information.
  4 in total

1.  Disposition of 5-aminosalicylic acid by olsalazine and three mesalazine preparations in patients with ulcerative colitis: comparison of intraluminal colonic concentrations, serum values, and urinary excretion.

Authors:  L Staerk Laursen; M Stokholm; K Bukhave; J Rask-Madsen; K Lauritsen
Journal:  Gut       Date:  1990-11       Impact factor: 23.059

2.  Disposition of mesalazine from mesalazine-delivering drugs in patients with inflammatory bowel disease, with and without diarrhoea.

Authors:  M C Rijk; A van Schaik; J H van Tongeren
Journal:  Scand J Gastroenterol       Date:  1992-10       Impact factor: 2.423

3.  Comparison of delayed-release 5-aminosalicylic acid (mesalazine) and sulfasalazine as maintenance treatment for patients with ulcerative colitis.

Authors:  S A Riley; V Mani; M J Goodman; M E Herd; S Dutt; L A Turnberg
Journal:  Gastroenterology       Date:  1988-06       Impact factor: 22.682

4.  Concentrations of 5-ASA and Ac-5-ASA in human ileocolonic biopsy homogenates after oral 5-ASA preparations.

Authors:  M De Vos; H Verdievel; R Schoonjans; M Praet; M Bogaert; F Barbier
Journal:  Gut       Date:  1992-10       Impact factor: 23.059
  4 in total
  1 in total

Review 1.  Nephrolithiasis as a common urinary system manifestation of inflammatory bowel diseases; a clinical review and meta-analysis.

Authors:  Mahboube Ganji-Arjenaki; Hamid Nasri; Mahmoud Rafieian-Kopaei
Journal:  J Nephropathol       Date:  2017-04-12
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.